BioGaia: One of the World’s Most Widespread Infections – BioGaia’s Gastrus Improves Treatment

STOCKHOLM--()--Regulatory News:

BioGaia (STO:BIOG-B):  

Two new studies in patients infected with Helicobacter pylori show that supplementation with the new probiotic Lactobacillus reuteri Gastrus reduced side effects of eradication therapy by a third.

"We found that Gastrus is able to exert an inhibitory effect on H. pylori growth and that when administered with the eradication therapy, it induces a significant reduction of antibiotic associated side effects and increases eradication rates," says Dr Ruggiero Francavilla at the Bari University Hospital in Italy.

In the studies, conducted at university hospitals in Italy and Egypt, the patients supplemented with Lactobacillus reuteri Gastrus reported less symptoms and less side effects from the eradication therapy compared to patients given placebo. The probiotic decreased both frequency and severity of side effects and was especially effective in reducing pain, diarrhoea and bloating.

Supplementation with Lactobacillus reuteri Gastrus also further improved eradication of the Helicobacter pylori infection.

“Helicobacter pylori is one of the most widespread infections in the world and a serious problem in many countries. One of the difficulties is that eradication rates are declining, mainly because of antibiotic resistance, and there is a need for new treatment regimens. There are now two positive independent studies with our new Gastrus product as an adjunct to H. pylori eradication therapy, laying the foundation for a successful launch of Gastrus”, says Peter Rothschild, President BioGaia.

Links to the studies:

Francavilla: Journal of Clinical Gastroenterology, 27 Nov 2013

(http://journals.lww.com/jcge/Abstract/publishahead/Lactobacillus_reuteri_Strain_Combination_In.98717.aspx)

Emara: Therapeutic Advances in Gastroenterology, 4 Sept 2013 (http://tag.sagepub.com/content/early/2013/09/04/1756283X13503514.abstract)

More information on Helicobacter pylori infection (http://www.biogaia.com/sites/biogaia.com/files/Helicobacter_pylori.pdf), study details (http://www.biogaia.com/sites/biogaia.com/files/Study-facts_Francavilla_Emara.pdf) and interviews with Dr Francavilla (http://youtu.be/eOwfepPy-F0) and Dr Emara (http://youtu.be/8CR14x7HDt8) are found through the links in this press release.

Latest press releases from BioGaia

2013-11-15 BioGaia signs exclusive agreement for drops and tablets in Brazil

2013-11-12 BioGaia invests in development of a drug against NEC

2013-10-29 BioGaia expands network within oral health field

BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 5 December 2013, 4:00 pm CET.

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com

This information was brought to you by Cision http://news.cision.com

Contacts

BioGaia
Peter Rothschild
Chief Executive Officer
46 8 555 293 00

Sharing

Contacts

BioGaia
Peter Rothschild
Chief Executive Officer
46 8 555 293 00